Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Launched by MAYO CLINIC · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how a hormone called glucagon affects blood sugar levels and insulin secretion in people who do not have type 2 diabetes but may be at risk, such as those with prediabetes. The goal is to understand how glucagon and insulin work together to manage blood sugar levels when a person has not eaten for a while, which is important for preventing complications associated with diabetes.

To participate in this study, individuals should be between the ages of 9 and 74 and have either normal or slightly elevated blood sugar levels. However, those who are currently taking medications to lower blood sugar or have certain health conditions, such as recent cancer or major surgeries, will not be eligible. If you join the study, you can expect to undergo tests that help researchers learn more about your body’s response to glucagon and insulin. This information could help improve treatments for people at risk of developing type 2 diabetes in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance
• Exclusion Criteria:
• • HbA1c less than 6.5%
• • Use of any glucose-lowering agents including metformin or sulfonylureas.
• • For female subjects: positive pregnancy test at the time of enrollment or study
• • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
• • Active systemic illness or malignancy.
• • Symptomatic macrovascular or microvascular disease.

Trial Officials